Title:A Mechanism-based Perspective on the Use of Flavonoids in the Treatment of Diabetes and its Complications
Volume: 22
Issue: 2
Author(s): Sandesh Kumar Pattanaik, Manisha Prajapati Anil, Sudipta Jena and Diptirani Rath*
Affiliation:
- School of Pharmaceutical Sciences, Siksha ‘O’ Anusandhan Deemed to be University, Bhubaneswar, Odisha, 751003,
India
Keywords:
Flavones, flavanones, flavonols, flavanonols, type 1 diabetes, type 2 diabetes, gestational diabetes.
Abstract: Diabetes is a chronic, irreversible, non-infectious metabolic syndrome associated with
low insulin production by the pancreas or due to insulin resistance. The management landscape
for diabetes is swiftly evolving due to ongoing advancements. Conventional treatment approaches
have struggled to fully address the root causes of the disease while also carrying significant risks
of adverse effects. Flavonoids are an extensive class of phytonutrients present in grains, vegetables,
fruits, cocoa, tea, wine, and nuts. Many studies have reported that flavonoids have shown diversified
pharmacological activity in recent years. Thus, this review will give you an overview of
the significant anti-diabetic potential of promising flavonoids. Various search engines such as
PubMed, Scopus, Google Scholar, and WoS have been explored by using the keywords “apigenin,”
“luteolin,” “naringenin,” “hesperidin,” “kaempferol,” “quercetin,” “myricetin” and “taxifolin”
with “anti-diabetic.” The anti-diabetic activity of flavonoids is attributed to various mechanisms,
including α glucosidase, α-amylase inhibitory effects, GLUT4 expression, antioxidant, and apoptosis.
However, their inadequate biopharmaceutical qualities make their effectiveness in clinical
translation constrained. This review aims to highlight plant-derived flavonoids through in-vitro, in
vivo, and clinical insights. Additionally, the review highlights the recent advancement in the drug
delivery system in diabetes to overcome the limitation of flavonoids.
